$59.95
0.35% day before yesterday
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US09061G1013
Symbol
BMRN

Biomarin Pharmaceutical Stock price

$59.95
+4.43 7.98% 1M
+5.85 10.81% 6M
-5.78 8.79% YTD
-7.07 10.55% 1Y
-44.39 42.54% 3Y
-27.63 31.55% 5Y
-45.35 43.07% 10Y
+48.54 425.42% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.21 0.35%

New AI Insights on Biomarin Pharmaceutical Insights AI Insights on Biomarin Pharmaceutical

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$11.5b
Enterprise Value
$10.6b
Net debt
positive
Cash
$1.5b
Shares outstanding
192.1m
Valuation (TTM | estimate)
P/E
22.1 | 20.0
P/S
3.7 | 3.6
EV/Sales
3.4 | 3.3
EV/FCF
12.9
P/B
1.9
Financial Health
Equity Ratio
81.0%
Return on Equity
7.5%
ROCE
9.2%
ROIC
8.4%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$3.1b | $3.2b
EBITDA
$649.5m | $763.3m
EBIT
$625.3m | $689.7m
Net Income
$520.4m | $576.1m
Free Cash Flow
$825.8m
Growth (TTM | estimate)
Revenue
12.4% | 13.4%
EBITDA
41.7% | 24.5%
EBIT
52.7% | 21.0%
Net Income
61.5% | 35.0%
Free Cash Flow
174.5%
Margin (TTM | estimate)
Gross
81.3%
EBITDA
21.0% | 23.6%
EBIT
20.2%
Net
16.8% | 17.8%
Free Cash Flow
26.7%
More
EPS
$2.7
FCF per Share
$4.3
Short interest
5.4%
Employees
3k
Rev per Employee
$940.0k
Show more

Is Biomarin Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Biomarin Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Biomarin Pharmaceutical forecast:

27x Buy
79%
7x Hold
21%

Analyst Opinions

34 Analysts have issued a Biomarin Pharmaceutical forecast:

Buy
79%
Hold
21%

Financial data from Biomarin Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,094 3,094
12% 12%
100%
- Direct Costs 578 578
0% 0%
19%
2,516 2,516
16% 16%
81%
- Selling and Administrative Expenses 964 964
3% 3%
31%
- Research and Development Expense 903 903
16% 16%
29%
650 650
42% 42%
21%
- Depreciation and Amortization 24 24
50% 50%
1%
EBIT (Operating Income) EBIT 625 625
53% 53%
20%
Net Profit 520 520
61% 61%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Biomarin Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomarin Pharmaceutical Stock News

Neutral
Business Wire
about 14 hours ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN). Under the terms of the proposed transaction, shareholders of Amicus will receive $14.50 in cash for each shar...
Positive
Seeking Alpha
5 days ago
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.
Neutral
Seeking Alpha
8 days ago
BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript
More Biomarin Pharmaceutical News

Company Profile

BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Head office United States
CEO Alexander Hardy
Employees 3,040
Founded 1997
Website www.biomarin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today